Sun Pharmaceutical Industries Limited signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at an enterprise value of US$11.75 billion. Under the agreement, Sun Pharma will acquire all outstanding shares of Organon. The acquisition is expected to significantly strengthen Sun Pharma’s global presence across innovative medicines, women’s healthcare, branded generics and biosimilars, while expanding its footprint in key international markets.
Strategic Acquisition to Accelerate Global Growth
The proposed acquisition aligns with Sun Pharma’s long-term strategy of expanding its Innovative Medicines business and reinforcing its leadership in the Established Brands and Branded Generics segment. The transaction will enable Sun Pharma to enter the rapidly growing biosimilars market as one of the Top 10 global players. By integrating Organon’s portfolio, manufacturing capabilities and international commercial network, the company aims to accelerate sustainable growth and create long-term value for stakeholders.
Organon Brings Strong Global Portfolio
Organon was established in 2021 following its spin-off from Merck & Co., Inc. (known as MSD outside the United States and Canada). Today, the company operates as a global healthcare leader with a strong focus on women’s health. Its portfolio comprises more than 70 products spanning women’s health, general medicines and biosimilars, which are commercialised in over 140 countries. Organon’s largest markets include the United States, Europe, China, Canada and Brazil. The company also operates six manufacturing facilities across the European Union and emerging markets, providing a robust manufacturing and supply chain platform.
Enhancing Sun Pharma’s Global Healthcare Leadership
With the addition of Organon, Sun Pharma expects to strengthen its diversified healthcare portfolio while expanding access to high-quality medicines worldwide. The acquisition will combine Organon’s strong global brands, customer relationships and healthcare expertise with Sun Pharma’s manufacturing excellence, research capabilities and global commercial network. Together, the combined organisation aims to improve healthcare access, strengthen affordability and deliver innovative treatment solutions across multiple therapeutic segments.
A Transformational Opportunity
Dilip Shanghvi, Executive Chairman of Sun Pharma, said, “The transaction represents a significant opportunity for Sun Pharma to build on its vision of ‘Reaching People and Touching Lives’. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe bringing the two organisations together will create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long-term growth.”
Kirti Ganorkar, Managing Director of Sun Pharma, described the acquisition as a strategic milestone in the company’s global expansion. “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We also see significant opportunities to leverage Organon’s talented workforce while unlocking meaningful revenue synergies over the coming years,” Ganorkar mentioned.
Organon Board Supports the Transaction
Carrie Cox, Executive Chair of Organon, said the agreement delivers immediate value to shareholders while ensuring long-term continuity for the company’s business. “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, while continuing our commitment to delivering impactful medicines and healthcare solutions,” Cox said.
Expanding Global Footprint and Future Opportunities
The acquisition positions Sun Pharma to significantly strengthen its global healthcare business by expanding its presence in women’s health, biosimilars, innovative medicines and branded generics. As per the press release, Organon’s established international footprint, diversified product portfolio and manufacturing infrastructure are expected to complement Sun Pharma’s existing strengths. The combined company is well positioned to accelerate innovation, expand market reach and create sustainable long-term value for patients, healthcare providers, investors and other stakeholders worldwide.
